Clinical Trials
15 trialsNCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
NCT03420014 2023-10-10
FIBROSARC US
Philogen S.p.A.
Phase 2 Unknown
NCT05548179 2023-03-06
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
Power Life Sciences Inc.
Unknown
NCT05204524 2022-01-24
Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma
ChineseAMS
Phase NA Unknown
NCT04935333 2021-09-10
MYOSARCII
Igenomix
Unknown
NCT04214457 2021-09-05
MYOSARC
Igenomix
Unknown
NCT03989596 2021-02-01
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT03651375 2021-01-22
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT01883518 2019-11-20
ADCVCTAST
N.N. Petrov National Medical Research Center of Oncology
Phase 1/2 Unknown
NCT02983539 2018-07-02
CTCS
AC Camargo Cancer Center
Unknown
NCT02587169 2015-10-27
GEIS-27
Broto, Javier MartÃn, M.D.
Phase 1/2 Unknown
NCT00410462 2014-08-08
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT00003718 2014-01-06
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00033709 2014-01-06
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00900211 2013-08-26
Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX
National Cancer Institute (NCI)
Unknown